March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive clinical trial program at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025, in Chicago, IL, March 29-31, 2025.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
<>Additional ACC.25 presentations include:
-
An analysis of FINE-HEART, an integrated, pooled, exploratory, participant-level analysis across three pivotal Phase III clinical trials with finerenone—FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD,
-
A post-hoc analysis of FIDELITY, a pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials that evaluated the long-term effects of KERENDIA on CV outcomes in patients with chronic kidney disease (CKD) in type 2 diabetes (T2D), and
-
Real-world research on patients with worsening HF within a large healthcare delivery system from 2012-2021.
Details on abstracts presented by Bayer at ACC.25 include
-
Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
-
Efficacy and safety of finerenone according to New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction during the session "Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
-
Finerenone, bilirubin, and heart failure with mildly reduced or preserved ejection fraction: analysis from FINEARTS-HF during the session "Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
-
Efficacy of finerenone according to left atrial size in patients with heart failure and mildly reduced or preserved ejection fraction: An analysis of the FINEARTS-HF trial during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"
-
Finerenone in patients with HFmrEF/HFpEF with and without atrial fibrillation: a prespecified analysis of FINEARTS-HF during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"
-
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: An analysis of FINEARTS-HF during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"
-
Efficacy and safety of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified anemia-specific analysis of the FINEARTS-HF trial during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"
-
Effect of finerenone on N-terminal pro-B-type natriuretic peptide in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial during the session "Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"
-
Temporal changes in biomarkers and quality of life prior to adverse clinical outcomes in heart failure with mildly reduced or preserved ejection fraction during the session "Heart Failure and Cardiomyopathies 04"
-
Mode of death in patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial during the session "Heart Failure With Preserved Ejection Fraction: Utility of Hemodynamic Data, Treatment Options and Mode of Death"
-
Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolism: The FINE-HEART pooled analysis during the session "Heart Failure and Cardiomyopathies 09"
-
Worsening heart failure events in adults with mild-to-moderate chronic kidney disease during the session "Heart Failure and Cardiomyopathies 10"
-
Mechanisms of cardiovascular benefit with finerenone – a causal mediation analysis of the joint effects of systolic blood pressure and albuminuria reduction during the session: Optimizing Cardiovascular Risk Across the Diabetes/Cardio-Kidney-Metabolic Spectrum
For more information on American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025, please visit accscientificsession.acc.org/.
Find more information on Bayer at https://pharma.bayer.com/.
1. Bayer Pharmaceuticals. Kerendia (finerenone) [package insert]. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf. Accessed March 11, 2025.